Deals channel feed

In­vestors give ail­ing Unum a lease on life and a whole new suite of ex­per­i­men­tal can­cer drugs

5 years ago
Financing

Pfiz­er re-ups on Mis­sion Ther­a­peu­tics col­lab­o­ra­tion, lead­ing a $15M round and grab­bing first dibs on DUBs

5 years ago
Financing

A boom­ing Drag­on­fly is tak­ing its TriN­KETs to Copen­hagen as the lat­est Bris­tol My­ers pact spurs ex­pan­sion plans — out­side the US

5 years ago
Cell/Gene Tx

An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new bi­ol­o­gy’

5 years ago
R&D
Pharma

Back to the im­munol­o­gy draw­ing board, Ab­b­Vie inks dis­cov­ery deal with old Al­ler­gan part­ner

5 years ago
Discovery

In an un­ex­pect­ed twist, CSL buys world­wide rights to uniQure's PhI­II he­mo­phil­ia B gene ther­a­py in $2B-plus deal

5 years ago
Cell/Gene Tx

Is it re­al­ly over? La Jol­la signs ac­qui­si­tion with Tetraphase af­ter out­bid­ding Acel­Rx, Melin­ta

5 years ago

Burned by Alzheimer’s fail­ures, a cau­tious Mer­ck turns to a start­up biotech for some pre­clin­i­cal neu­ro pro­grams

5 years ago
R&D
Discovery

Daniel O’Day snatch­es an­oth­er I/O com­pa­ny, buy­ing half of a pi­o­neer­ing can­cer drug dis­cov­er­er's biotech

5 years ago
People

Sanofi bets $425M cash on a trans­for­ma­tion-style next-gen vac­cine deal — as the Big Phar­ma team makes a point

5 years ago

Sarep­ta ex­pands gene ther­a­py toolk­it, bets $72.5M to hitch a ride on Co­di­ak's ex­o­some tech

5 years ago
Cell/Gene Tx

What’s this? A ri­val bid­der heads back to the ta­ble with a bet­ter of­fer for Tetraphase. An­tibi­otics show faint signs of life

5 years ago

Ab­b­Vie sweeps out ex­per­i­men­tal gas­tro drugs in a post-merg­er pipeline cleanup. And they can like­ly be yours for the right price

5 years ago
R&D

Ab­b­Vie-Al­ler­gan com­plete, but crit­ics con­tin­ue to raise an­ti-com­pet­i­tive con­cerns

5 years ago
Pharma

Ab­b­Vie beefs up the im­munol­o­gy pipeline, bet­ting up to $865M on a PhII-ready drug — and fu­el­ing a biotech stock fren­zy

5 years ago

Two Bay Area up­starts out to de­liv­er on cell ther­a­py 2.0 join forces on a quest: pur­su­ing a Holy Grail in on­col­o­gy R&D

5 years ago
Cell/Gene Tx

Take­da spins out a pipeline of ‘in­ter­est­ing but still dif­fi­cult’ psych drugs in $2B deal as it wraps up a post-merg­er R&D shake­out

5 years ago
R&D

Bil­lions on the ta­ble, GSK’s Hal Bar­ron antes $120M cash to part­ner with a spe­cial­ist in syn­thet­ic lethal­i­ty

5 years ago

Can­cer drug­mak­er Agios of­fers promis­ing da­ta from two stud­ies test­ing blood dis­or­der drug

5 years ago
R&D

Take­da con­tin­ues post-Shire sell­off, inch­ing clos­er to $10B goal

5 years ago

It's all about the heart: Di­a­betes ma­jor No­vo Nordisk bets $725M up­front to buy car­dio-fo­cused As­traZeneca spin­off

5 years ago
R&D

Sanofi sharp­ens fo­cus on bis­pecifics, and Chi­na, with Al­pham­ab deal

5 years ago
China

An­a­lysts cheer as Ab­b­Vie pays $750M cash to al­ly it­self with Gen­mab on a pipeline of can­cer drugs, with bil­lions more on the ta­ble

5 years ago

CSL Behring snaps up a close­ly-held biotech part­ner and its IL-6 drug — for trans­plant re­jec­tion

5 years ago
First page Previous page 89909192939495 Next page Last page
A service from the Financial Times